Redhill Capital

Name

Redhill Capital

Legal name

Redhill Capital

Website

https://redhillcapital.cn

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Venture Capital Fund Management

NAICS

Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Healthcare venture capital
• Medical technology investing
• Early-stage equity investment
• Biopharma fund management
• Innovative medical devices

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Fund Management Fees: Management fees charged on AUM (Assets Under Management) from multiple RMB and USD funds
2. Carried Interest (Carry): Performance-based carried interest from successful portfolio company exits including IPOs and M&A transactions

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Redhill Capital is a China-based venture capital firm that manages six RMB-denominated funds and one USD fund, investing in early and growth-stage innovative healthcare and medical technology companies. The firm deploys roughly 70% of capital into innovative medical technology (medical devices, IVD, medical AI, medical robotics, digital health) and 30% into innovative drugs. It provides portfolio companies with capital, talent recruitment support, management framework development, and facilitation of next-round financing.

Product overview

Redhill Capital is a venture capital firm specializing in early-stage healthcare investments. The company manages six RMB funds and one USD fund, having invested in approximately 60 innovative medical companies. Their portfolio spans medical devices, in vitro diagnostics, medical AI, innovative drugs, and new medical services. Key portfolio products include Manteia's adaptive radiation therapy systems, Vistel's EyeWisdom ophthalmic AI solution, ShanSiWei's CMOS flat panel detectors, LiangYiHui's cancer digital platform, and Kefu's home medical devices. The investment thesis focuses 70% on innovative medical technology (medical devices, cross-innovative technologies) and 30% on innovative drugs.

Differentiator

Problem solved

Functional benefit

Products and services

• Redhill Capital Healthcare VC Funds (RMB and USD) Venture capital fund management services investing in early and growth-stage innovative healthcare and medical technology companies in China. Currently manages six RMB funds and one USD fund with approximately 60 portfolio companies. Capital is allocated roughly 70% to innovative medical technology (medical devices, IVD, medical AI, robotics, digital health) and 30% to innovative drugs. Targeted at institutional and high-net-worth LPs and at portfolio companies seeking growth equity and strategic support.

Quantifiable outcome

• Portfolio companies achieving 2x+ valuation increase within first year of investment
• +2 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and major.

• Greater Bay Area Healthcare & Life Sciences Industry-Finance Alliance (广州大健康与生命科学产融联盟)coreStrategic or Co-development PartnerIndustry alliance initiated by Redhill Capital in December 2021, bringing together healthcare innovation institutions, research hospitals, and investment firms in the Greater Bay Area to accelerate biotech translational research and industry development.
• Jinan University (暨南大学)majorStrategic or Co-development PartnerCollaboration on research translation and university spin-off development through the GBA Healthcare Industry-Finance Alliance, focusing on bridging academic research with commercialization.
• Southern Medical University珠江医院再生医学研究所majorStrategic or Co-development PartnerAcademic-medical partnership through the industry alliance focusing on regenerative medicine research translation and investment opportunities.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Qiming Venture Partners: Leading China healthcare-focused VC firm with multi-billion USD AUM and a dedicated healthcare team investing from seed through growth stages. Directly comparable as a sector-specialist VC frequently co-investing with Redhill (e.g., Vistel, Liangyihui).
• LYFE Capital: Healthcare-focused venture and growth capital firm in China investing across medical devices, biopharma, and diagnostics. Comparable fund size and sector focus, with similar early-to-growth stage thesis in Chinese medical innovation.
• C-Bridge Capital: Healthcare-dedicated investment firm covering both venture and growth/buyout stages in China. Directly comparable as a sector-specialist with overlapping portfolio themes in innovative drugs and medical devices.
• Legend Capital: China-focused venture and growth capital firm (formerly Lenovo Investment) with deep healthcare coverage including devices, diagnostics, and biopharma. Comparable stage focus, fund size, and sector approach in Chinese medical innovation.
• Ally Bridge Group: Healthcare-focused investment firm spanning China and US with venture and crossover strategies in medical devices and biopharma. Directly comparable as a healthcare-specialist with cross-border capabilities.
• Vivo Capital: Healthcare-dedicated investment firm with strong China and US presence, investing across venture, growth, and public stages in pharma, devices, and healthcare services. Comparable as a global healthcare-specialist.

Broad incumbents

• OrbiMed: Global healthcare-dedicated investment firm across venture, growth, and public equities. Comparable as a sector-specialist incumbent, though with a much larger global platform and broader stage coverage than Redhill.
• Hillhouse Capital: Large diversified China-focused investment firm with a dedicated healthcare team covering pharma, devices, and healthcare services. Overlaps with Redhill in healthcare VC but operates at much greater scale across multiple sectors.
• Sequoia Capital China: Premier Chinese venture firm and a key LP/strategic partner of Redhill. While a broad incumbent across all sectors, its dedicated healthcare team invests in many of the same medical startups, making it both a deal collaborator and competitor.

Regional players

• 3H Health Investment: Healthcare-focused venture firm with strong ties to Greater Bay Area medical ecosystem. Comparable as a sector-specialist with regional concentration overlapping Redhill's Guangzhou base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redhill Capital